Medication info
Losatec Plus F Tablets

Losatec Plus F Tablets

Prescription medicationTabletOral
Ingredient · strength
Losartan Potassium›100mg / 1 tabletHydrochlorothiazide›25mg / 1 tablet
Manufacturer / importer
Daewon Biotech Co., Ltd.
Appearance
Pale yellow oval film-coated tablets
Packaging
30 tablets/bottle, 100 tablets/bottle
Approval status
Active

MFDS item code 202001999 · Approved 2020.03.20 · Insurance code 057600650

Summary

Main use
Treatment of hypertension not controlled with monotherapy
Who takes it
Adults · Children
Adult dose
○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine only when the desired effect has not been achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or greater. Administration is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in these patients because the initial dose of losartan potassium for patients with hepatic impairment requiring dosage adjustment, 25 mg, cannot be provided with this medicine.
Child dose
○ Children (under 18 years) As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Ingredients

Manufacturer
Daewon Biotech Co., Ltd.

Efficacy & effects

Treatment of hypertension not controlled with monotherapy

  • Hypertension
View approved original text

This medication is used for patients with hypertension whose blood pressure is not adequately controlled on monotherapy.

How to take

Adult dose

○ Adults The usual dose of this medicine is 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. Doses exceeding losartan potassium 100 mg/hydrochlorothiazide 25 mg per day are not recommended. The maximum blood pressure-lowering effect generally occurs approximately 3 weeks after the start of treatment. This medicine may be administered with other antihypertensive agents and may be taken with or without food. To minimize adverse reactions, start this medicine only when the desired effect has not been achieved with monotherapy. 1. Replacement therapy: Concomitant therapy with individually titrated doses of losartan potassium and hydrochlorothiazide may be replaced with this medicine. 2. Patients whose blood pressure is not controlled with losartan or hydrochlorothiazide monotherapy: Start with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 3. Patients whose blood pressure is not controlled with losartan potassium 100 mg monotherapy: Start with losartan potassium 100 mg/hydrochlorothiazide 12.5 mg once daily. If blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. 4. Patients whose blood pressure is not controlled with hydrochlorothiazide 25 mg once daily, or who have hypokalemia despite blood pressure control at this dose: Treatment may be started with 1 tablet of losartan potassium 50 mg/hydrochlorothiazide 12.5 mg once daily, which allows the hydrochlorothiazide dose to be reduced without reducing the overall blood pressure-lowering effect. The clinical response to losartan potassium 50 mg/hydrochlorothiazide 12.5 mg should then be monitored continuously; if blood pressure remains uncontrolled after 3 weeks of treatment, the dose may be increased to a maximum of 1 tablet of losartan potassium 100 mg/hydrochlorothiazide 25 mg once daily. ○ Patients with renal impairment Use the usual dose when creatinine clearance is 30 mL/min or greater. Administration is not recommended in patients with more severe renal impairment, as loop diuretics are preferable to thiazide drugs in these patients. ○ Patients with hepatic impairment Administration is not recommended in these patients because the initial dose of losartan potassium for patients with hepatic impairment requiring dosage adjustment, 25 mg, cannot be provided with this medicine.

Child dose

○ Children (under 18 years) As there is no experience with use in children and adolescents, the losartan-hydrochlorothiazide combination should not be administered to children or adolescents.

Precautions

This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it must be discontinued immediately upon confirmation of pregnancy. It is safe not to administer this medication to patients with certain diseases or conditions. For example, patients with severely impaired kidney function, severe liver dysfunction, and those with certain allergy histories should not use this medication. Patients with very low blood pressure or reduced blood volume, patients with renal artery problems, and patients with liver diseases should exercise special caution when using this medication. During treatment, blood pressure, kidney function, and electrolyte levels should be regularly monitored, particularly any fluctuations in potassium levels. Due to the hydrochlorothiazide component, electrolyte imbalance, increased blood sugar, and elevated uric acid levels may occur, so any symptoms should be discussed with a physician. This medication has a strong effect on lowering blood pressure, which may lead to dizziness or drowsiness, especially shortly after starting treatment, so caution is needed when driving or operating machinery. Interactions may occur when taken with other medications, so especially when combined with potassium supplements, blood pressure medications, diuretics, or non-steroidal anti-inflammatory drugs, consultation with a physician is necessary. This medication is not recommended for use in children and adolescents, and older individuals may experience side effects slightly more frequently, necessitating caution. In case of overdose, symptoms such as low blood pressure and cardiac function abnormalities may occur, thus requiring immediate medical attention for appropriate treatment. During treatment, if there are plans for pregnancy or if pregnancy is suspected, consultation with a physician is essential. If breastfeeding, it is recommended to either stop breastfeeding or discontinue the medication. This medication may cause sensitivity to sunlight, increasing the risk of skin cancer; therefore, limiting sun exposure and frequently checking skin condition is important. Finally, this medication should be stored in its original container, out of the reach of children, and it is safest not to change the container arbitrarily.

Side effects

  • Craniosynostosis
  • Anuria
  • Hypotension
  • Renal failure
  • Death
  • Abdominal pain
  • Edema
  • Palpitations
  • Back pain
  • Dizziness
Show 132 more
  • Cough
  • Sinusitis
  • Upper respiratory infection
  • Rash
  • Angioedema
  • Skin peeling phenomenon
  • Hemolysis
  • Chest pain
  • Facial edema
  • Fever
  • Orthostatic hypotension
  • Syncope
  • Angina pectoris
  • Arrhythmia
  • Stroke
  • Myocardial infarction
  • Secondary atrioventricular block
  • Loss of appetite
  • Constipation
  • Toothache
  • Dry mouth
  • Dyspepsia
  • Flatulence
  • Gastritis
  • Vomiting
  • Fatigue
  • Anemia
  • Gout
  • Arm pain
  • Joint pain
  • Arthritis
  • Fibromyalgia
  • Hip pain
  • Joint swelling
  • Knee pain
  • Leg pain
  • Muscle cramps
  • Muscle weakness
  • Musculoskeletal pain
  • Myalgia
  • Shoulder pain
  • Muscle stiffness
  • Anxiety
  • Anxiety disorder
  • Ataxia
  • Confusion
  • Depression
  • Nightmares
  • Sensory loss
  • Insomnia
  • Decreased libido
  • Memory impairment
  • Migraine
  • Hyperexcitability
  • Panic disorder
  • Sensory disturbance
  • Peripheral neuropathy
  • Sleep disorder
  • Drowsiness
  • Tremors
  • Shortness of breath
  • Nasal bleeding
  • Nasal congestion
  • Throat discomfort
  • Respiratory congestion
  • Rhinitis
  • Venous obstruction
  • Chest discomfort
  • Alopecia
  • Dermatitis
  • Dry skin
  • Petechiae
  • Erythema
  • Flushing
  • Photosensitivity reaction
  • Itching
  • Sweating
  • Urticaria
  • Blurred vision
  • Ocular pain
  • Burning sensation
  • Conjunctivitis
  • Vision impairment
  • Taste disturbance
  • Tinnitus
  • Erectile dysfunction
  • Nocturia
  • Pollakiuria
  • Urinary tract infection
  • Weakness
  • Pancreatitis
  • Jaundice
  • Sialadenitis
  • Spasm
  • Gastrointestinal irritation
  • Aplastic anemia
  • Agranulocytosis
  • Leukopenia
  • Thrombocytopenia
  • Purpura
  • Necrotizing vasculitis
  • Fever
  • Pneumonia
  • Pulmonary edema
  • Acute respiratory distress syndrome
  • Hyperglycemia
  • Diabetes
  • Muscle cramps
  • Nervousness
  • Renal failure
  • Renal dysfunction
  • Interstitial nephritis
  • Stevens-Johnson syndrome
  • Erythema multiforme
  • Toxic epidermal necrolysis
  • Temporary blurred vision
  • Yellow vision
  • Acute myopia
  • Acute angle-closure glaucoma
  • Choroidal exudate
  • Hypotension
  • Tachycardia
  • Angioedema
  • Vasculitis
  • Anaphylactic reaction
  • Hepatitis
  • Intestinal vascular edema
  • Dry cough
  • Erythema nodosum
  • Hyperkalemia
  • Hyponatremia
  • Rhabdomyolysis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light, so it should be stored in a container that blocks light. Additionally, it is best to keep the medication at room temperature, which should not be too cold or too hot, ideally between 1 degree to 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow oval film-coated tablets

Package unit

30 tablets/bottle, 100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.